Andrew Clark in New York
Thursday June 7, 2007
The Guardian
The head of the US food and drug administration has admitted his staff attempted to smear a scientist who raised doubts about Avandia - the GlaxoSmithKline diabetes drug that has been linked with a high incidence of heart attacks.
Senior executives from the FDA and Glaxo faced a gruelling morning of questioning by members of Congress at a hearing convened by the House oversight committee in Washington yesterday.
Members of the committee attacked "negligence" and systemic failures in a lack of warnings to patients about the risks of Avandia, which generated £1.4bn in revenue for Glaxo last year.
Dr. Greens comment: So the next time you see something is or isn't FDA approved, don't be too impressed. They are not unbiased.
No comments:
Post a Comment